- A Phase 2 trial, called IMvigor 210, evaluating Roche's (OTCQX:RHHBY) Breakthrough Therapy-tagged atezolizumab (MPDL3280A) in patients with locally advanced or metastatic urothelial bladder cancer (UBC) who had progressed on initial treatment met its primary endpoint of objective response rate (ORR). In addition, patients with high amounts of PD-L1 (Programmed Death Ligand-1) correlated with increased response to atezolizumab.
- The results will be presented at an upcoming medical conference and will be reviewed with regulators as soon as possible to clarify an approval path.
- A Phase 3 study, IMvigor 211, assessing atezolizumab with standard-of-care chemo in patients with relapsed UBC is ongoing. Another Phase 3, IMvigor 010, in patients with early stage muscle-invasive bladder cancer who are PD-L1 positive and at risk of recurrence is expected to start shortly.
- Bladder cancer is the ninth most common cancer globally, with 430K new cases each year resulting in 145K deaths.